Saturday, July 11, 2026

Drug profile · INN

orforglipron calcium

orforglipron calcium (FOUNDAYO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 1
Drug details — orforglipron calcium
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

orforglipron calcium (FOUNDAYO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN orforglipron calcium
Brand FOUNDAYO
Route ORAL
Formulation TABLET

Approval history

Authority Status Date
FDA approved

Recent coverage

Frequently asked questions

What is orforglipron calcium?

orforglipron calcium (FOUNDAYO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for orforglipron calcium?

FOUNDAYO is a marketed brand name for orforglipron calcium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of orforglipron calcium?

orforglipron calcium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.